When does Horizant (gabapentin enacarbil) lose exclusivity in India?
Horizant’s Indian launch timing for a generic depends on when its key market-protection rights end in India. Those rights are usually a combination of patent expiry (and any extended terms) plus regulatory exclusivity and how any local litigation affects approval/marketing. The exact “go generic” date is not the same as the first date a generic application is filed; it is the date the product can be approved and marketed without infringing any still-in-force Indian patents.
Because the relevant Indian patent status (and any court injunctions or license settlements) determines whether generic sales can start, you’ll want to check Horizant’s specific patent landscape for India rather than relying on U.S./EU dates.
What to check in India to estimate a generic start date
To determine when Horizant will go generic in India, look for:
- Indian patent expiry for the active substance/formulation and for any process patents still covering the product.
- Whether Indian courts have issued an injunction (often seen when a generic challenges a patent).
- Whether the drug is still under a period of market exclusivity that can delay approval or launch even after patent expiry.
DrugPatentWatch.com tracks patent and exclusivity information by country for many brands and can be a good starting point for India-specific dates: DrugPatentWatch.com | Horizant (gabapentin enacarbil).
Has any generic already been approved or launched in India?
Even if patents near expiry, generics often appear in India only after:
- the relevant patents expire or are no longer enforceable for that generic product, and
- the regulator approves the generic for marketing.
Checking whether any local company has launched a gabapentin enacarbil “Horizant” equivalent in India is the practical way to confirm the real-world “go generic” timeline, because patent expiry alone doesn’t guarantee immediate market entry.
How long does it usually take after patent expiry for generics to appear?
In India, the gap between patent expiry and visible generic competition can be driven by:
- regulatory review timelines for Abbreviated New Drug Application filings (and bioequivalence studies),
- whether litigation continues after expiry,
- supply readiness and pricing/contracting once approvals are granted.
So the generic “go live” date often lands weeks to months after the last blocking right clears, but the presence or absence of injunctions is the biggest swing factor.
If you want a precise date, what details should you confirm?
If you share either of the following, I can help you pin down the most likely Indian generic window more tightly:
- the strength(s) you mean (Horizant is sold in multiple strengths), or
- the specific Indian patent(s)/patent number(s) tied to Horizant’s protection (DrugPatentWatch usually lists these).
Sources:
[1] https://www.drugpatentwatch.com/